# XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

> **NCT00272051** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 620 (—)

## Conditions studied

- Metastases
- Colorectal Neoplasms
- Colorectal Carcinoma

## Interventions

- **DRUG:** SR57746A

## Key facts

- **NCT ID:** NCT00272051
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** —
- **Final completion:** 2004-05
- **Target enrollment:** 620 (—)
- **Last updated:** 2006-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00272051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00272051, "XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00272051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*